Send this article to a friend Print the page

Probably the most interesting and useful hepatic cell line discovered to date

♦ A unique and well established hepatic cell system able to produce early hepatic progenitor cells as well as completely mature human hepatocytes.

♦ The one-stop hepatic in-vitro model for:

- In-vitro ADME applications:
Inhibition assays
Drug metabolism and clearance
Metabolite ID

- In-vitro toxicity testing applications:
Hepatotoxicity (reactive metabolites, lipidosis, choleastasis etc)
Virology (HBV, HCV…)
Infection with hepatitis and other viruses for replication

- Liver assist devices/ BioArtificial Livers 
- Transgenic liver humanized animals with HepaRG™ cells
…. an ever-expanding range of applications!

♦ More economical, convenient, and predictable than fresh or cryopreserved primary human hepatocytes.

♦ Available in proliferative state to be expanded and differentiated in-house, or as cryopreserved, fully differentiated and ready-to-use hepatic cells.

Features of the HepaRG™ cells:
♦ Full array of functions, responses, and regulatory pathways of primary human hepatocytes including:
- Phase I and II, and transporter activities consistent with those found within a population of primary human hepatocytes.
- Intact response elements, PXR, CAR and PPARa.
♦ Form bile canaculi.
♦ Has the potential to express major properties of stem cells.
 High plasticity & complete transdifferentiation capacity.

HepaRG™ model system for cholestasis prediction

Time lapse (Total recording time: 2 hours).
Chlormoprazine superior to 40µM constricts the bile lumen and provokes cholestasis.
Constriction of canaliculus lumen has been observed in presence of CPZ after 2 hours.


Next HepaRG training session

Next training sessions on HepaRG will take place on the 25-26th of June. Register now ... Read more

A new compact comet assay for versatile genotoxicity testing and environmental monitoring

PRESS RELEASE – DECEMBER 2nd, 2014 Read more

Latest publications

  • The Multi-organ Chip - A Microfluidic Platform for Long-term Multi-tissue Coculture.Materne EM, Maschmeyer I, Lorenz AK, Horland R, Schimek KM, Busek M, Sonntag F, Lauster R, Marx U
    J Vis Exp., May 2015
  • Viral Entry of Hepatitis B and D Viruses and Bile Salts Transportation Share Common Molecular Determinants on Sodium Taurocholate Cotransporting PolypeptideYan X, Wang J, Zhu L, Lowrey JJ, Zhang Y, Hou W, Dong J, Du Y
    Lab Chip., May 2015
All publications on HepaRG

The cells were isolated from a donor afflicted with cholangiocarcinoma, and the novelty of the work performed by INSERM and Biopredic International scientists was to recognize their uniqueness and determine optimum culture conditions to support either growth or function as differentiated, adult hepatic cells.
Read more about HepaRG origins.

Thus, we have not interfered with their genome but utilized it advantageously, which may account for the cells’ karyotypic stability over a number of passages, and use of proliferating cells can provide a unique opportunity to confidently analyze signaling pathways and control mechanisms in the HepaRG.

Our scientists’ excitement grew as they realized that the HepaRG carried properties of early hepatic progenitor cells as well as mature hepatocytes, each condition allowing for uses of the cells that are unmatched. For example, HepaRG in the growth state tolerate infection by certain viruses which rarely enter differentiated, adult hepatocytes.

The predictability with which the cells can be differentiated, means that we can reliably provide cells with consistent characteristics at lower cost than primary human hepatocytes.

Scientists can utilize HepaRG in two forms, cryopreserved, differentiated cells that are convenient to both use and store, and growth-stage cells that can be grown in-house to desired populations and then frozen or differentiated as desired.

Biopredic International has complete User Instructions allowing for maximum quality of the differentiated cells, which require non expensive materials for their use. In fact, HepaRG™ cells actually reduce expenses compared with cryopreserved primary human hepatocytes.

When using growth-stage cells, a common question is their stability and useful life when they are differentiated, and with HepaRG, the answers are positive.

They can be grown and split through eight passages when used according to our recommended protocols and medium supplements (the base medium is off-the-shelf William's E mediu). The differentiation process is the same across passages and cells are usable for at least four weeks once differentiation is achieved.

Since the HepaRG have not undergone transfection or genome modification, they retain the range of hepatic cell responses, meaning that they have a very broad application versatility. For instance, they have shown the propensity to develop cholestasis or steatosis when exposed to appropriate agents, and they have been likewise used effectively in studies of sugar and lipid metabolism, in-vivo engraftment in rodents, 3D systems, bioartificial livers, chronic toxicity, etc.

To cap it off, Biopredic International maintains a large supply of HepaRG™ progenitor cells to serve as seed stock sufficient to meet the needs of the next decade, even if growth in demand is triple our projections.

HepaRG deliver unique, practical, and economical qualities which are unmatched today, and may be matched in 5-10 years, but that’s an unknown while the HepaRG are a known-as supported by 280+ papers and posters in the last years.

BIOPREDIC International   | | Phone: +33 (0)2 99 14 36 14 | Parc d'Affaires de la Bretèche 35760 Saint Grégoire FRANCE

HepaRGTM cell line

HPR101 HepaRG™ undifferentiated cells
HPR116 HepaRG™ differentiated cells

HPR116NS HepaRG™ differentiated No-Spin cells



Hepatotoxicity & mechanistic testing
Innovative modes of culture
Infectious diseases

Trouble shooting
Training session 

Publications reviews


MTA & Licenses 

Research projects

Contact us


Suscribe to our newsletter 

Follow us on:
Google +TwitterLinkedin
Home  |  Search  |  Site Map  |  Legal disclaimer